

Supplemental Table 1. Summary of killing of meningococci from strains H44/76 and 4243 by blood from individual immunized donors

Subject ID	CFU/mL at 3hr			
	Serogroup B, Strain H44/76		Serogroup C, Strain 4243	
	4 µM ACH-4471	50 µg/mL EZU	4 µM ACH-4471	50 µg/mL EZU
1	<100	131000	<100	60500
2	<100	65000	<100	112000
3	17800	92000	<100	79000
4	<100	231000	<100	237000
5	4800	126000	<100	98000
6	2900	45000	<100	105000
7	640	96000	5300	103000
8	14000	54000	25000	399000
9	<100	48000	<100	65000
10	<100	95000	<100	55500
11	<100	235000	<100	94500
12	<100	64100	<100	235000

	<100 CFU/ml (sterile culture)
	No increase in CFU/ml above control
	<10 fold increase above control
	10 to 100 fold increase above control


An average of 3561 CFU/ml of serogroup B strain H44/76 and 4903 CFU of serogroup C strain 4243 were added to blood at time 0. In the absence of inhibitor, all subjects had sterile cultures (<100 CFU/ml) after incubation of blood for 3 hrs. All subjects had been immunized with a meningococcal polysaccharide or conjugate vaccine that included serogroup C, and a meningococcal serogroup B vaccine (MenB-FHbp, subjects 1-6; or MenB-4C, subjects 7 to 12).

Supplemental Table 2. Summary of killing of meningococci from Ohio University and Quebec strains by blood from individual donors immunized with MenB-4C

	CFU/mL at 3hr			
	Ohio Univ. Strain		Quebec Strain	
Subject ID	4 µM ACH-4471	50 µg/mL EZU	4 µM ACH-4471	50 µg/mL EZU
7	<100	62000	<100	15000
8	4700	85000	<100	23000
9	<100	34000	<100	14500
10	2000	76000	<100	26500
11	1420	74000	<100	35828

	<100 CFU/ml (sterile culture)
	No increase in CFU/ml above control
	<10 fold increase above control
	10 to 100 fold increase above control

An average of 3084 CFU/ml of serogroup B Ohio University strain and 2737 CFU/ml of the Quebec strain were added to blood at time 0. In the absence of inhibitor, all subjects had sterile cultures (<100 CFU/ml) after incubation of blood for 3 hrs. All subjects had been immunized with meningococcal serogroup B vaccine (MenB-4C).



Supplemental Figure S1. Structure of ACH-4471. We acknowledge Drs. Jason Wiles, Avinash Phadke and Venkat Gadachanda of Achillion Pharmaceuticals for providing ACH-4471 (1).

Reference

1. Yuan X, Gavriilaki E, Thanassi JA, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Haematologica*. 2017;102(3):466-475.